A Phase 3 interventional study of Over-encapsulated 10 mg amlodipine besylate tablet and Matched placebo capsule for over-encapsulated celecoxib capsule in Hypertension, sponsored by Kitov Pharmaceuticals, Ltd.. Completed at 10 sites in United Kingdom. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-10-10.
Sponsored by Kitov Pharmaceuticals, Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.
Among the 187 studies testing amlodipine in Hypertension, this one is the 101st largest by enrollment of the 186 interventional ones that give a count, is one of 12 that started in 2014, is one of 69 in phase 3, and was the 122nd registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russia
Ages 50–70
Shenzhen Ausa Pharmed Co.,Ltd · Sites in China
Ages 45–74
Shenzhen Ausa Pharmed Co.,Ltd · Sites in China
Ages 45–74
Hyundai Pharm · Sites in Korea, Republic of
Ages 19+
Zentiva, k.s.
Ages 50–79 · Women only
By country, each count listing its studies:
Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 9 · Phase 3 71 · Phase 4 80
First in 1999; this study’s year is marked. 12 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 152 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 180 across the 186 interventional studies. Of the 156 that completed or were terminated, 53 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
120 of 187 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Kitov Pharmaceuticals, Ltd. as lead sponsor.
Kitov Pharmaceuticals, Ltd. has 1 study filed under Hypertension — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 187 studies testing amlodipine in Hypertension, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the effect of celecoxib on the efficacy and safety of amlodipine besylate in subjects with newly diagnosed hypertension requiring antihypertensive therapy.
This study was conducted to support a future marketing application for KIT-302. Kitov Pharma Ltd. (Kitov) is developing KIT-302, an oral fixed combination drug product (FCDP) consisting of the calcium channel blocker amlodipine besylate and the nonsteroidal anti-inflammatory drug (NSAID) celecoxib, as a "convenience reformulation" FCDP to facilitate and improve patient compliance with the once a day (qd) administration of its individual components, amlodipine and celecoxib.
The formulation of KIT-302 consists of amlodipine besylate and celecoxib co-formulated in a single immediate release tablet. However, for this study, two separate capsules were utilized: one containing a commercial celecoxib capsule (Celebrex®) or matched placebo capsule and one containing a commercial amlodipine besylate tablet (Norvasc®) or matched placebo tablet.
The study hypothesis was that treatment with the amlodipine besylate containing capsule plus the celecoxib containing capsule would reduce blood pressure (BP) in subjects with hypertension with an efficacy that is not substantially inferior to the effect of amlodipine besylate alone (i.e., the amlodipine containing capsule plus the matched placebo for the celecoxib capsule).
The United States (US) Food and Drug Administration (FDA) recently approved KIT-302, under the brand name Consensi® (amlodipine and celecoxib) tablets [New Drug Application (NDA) 210045] for the following indication: "patients for whom treatment with amlodipine for hypertension and celecoxib for osteoarthritis are appropriate. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions."
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Newly diagnosed hypertension that requires chronic pharmacological therapy. Specifically, the subject must meet both of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Over-encapsulated 10 mg amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks
Drug: Over-encapsulated 10 mg amlodipine besylate tablet · Drug: Over-encapsulated 200 mg celecoxib capsule
Over-encapsulated 10 mg amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
Drug: Over-encapsulated 10 mg amlodipine besylate tablet · Drug: Matched placebo capsule for over-encapsulated celecoxib capsule
Matched placebo capsule for over-encapsulated amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks
Drug: Over-encapsulated 200 mg celecoxib capsule · Drug: Matched placebo capsule for over-encapsulated amlodipine besylate tablet
Matched placebo capsule for over-encapsulated amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
Drug: Matched placebo capsule for over-encapsulated celecoxib capsule · Drug: Matched placebo capsule for over-encapsulated amlodipine besylate tablet
Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks
Also known as: Norvasc
Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
Also known as: Placebo
Over-encapsulated 200 mg celecoxib capsule once a day for two weeks
Also known as: Celebrex
Matched placebo capsule for over-encapsulated amlodipine besylate tablet once a day for two weeks
Also known as: Placebo
Mean Change in Average Daytime (9:00 to 21:00) Ambulatory Systolic Blood Pressure (SBPday) - Primary Endpoint
Time frame: Baseline and 2 weeks
Frequency of Adverse Events (Number of Participants Affected/Number of Participants at Risk)
Including any untoward medical occurrence in a participant administered study drug, which do not necessarily have a causal relationship with the study drug \[i.e., any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug, whether or not related to the study drug\].
Time frame: 1 month
Mean Change in Average 24-hour Ambulatory Systolic Blood Pressure (SBP24h)
Time frame: Baseline and 2 weeks
Mean Change in Average Night-time (01:00 to 06:00) Ambulatory Systolic Blood Pressure (SBPnight)
Time frame: Baseline and 2 weeks
Mean Change in Average 24-hour Ambulatory Diastolic Blood Pressure (DBP24h)
Time frame: Baseline and 2 weeks
Mean Change in Average Daytime (9:00 to 21:00) Ambulatory Diastolic Blood Pressure (DBPday)
Time frame: Baseline and 2 weeks
Mean Change in Average Night-time (01:00 to 06:00) Ambulatory Diastolic Blood Pressure (DBPnight)
Time frame: Baseline and 2 weeks
Mean Non-transformed Amlodipine Plasma Concentration
Time frame: 24 hours post-dose on Day 14
Mean Non-transformed Celecoxib Plasma Concentration
Time frame: 24 hours post-dose on Day 14
Mean Log-transformed Amlodipine Plasma Concentration
Time frame: 24 hours post-dose on Day 14
Mean Log-transformed Celecoxib Plasma Concentration
Time frame: 24 hours post-dose on Day 14
Mean Change in Average Daytime (9:00 to 21:00) Ambulatory Systolic Blood Pressure (SBPday) - Secondary Endpoint
Time frame: Baseline and 2 weeks
| Milestone | Amlodipine+Celecoxib | Amlodipine+Placebo | Placebo+Celecoxib | Placebo+Placebo |
|---|---|---|---|---|
| Started | 49 | 45 | 31 | 27 |
| Completed | 49 | 42 | 29 | 26 |
| Not completed | 0 | 3 | 2 | 1 |
| Withdrew: Adverse event | 0 | 2 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
| Withdrew: Not available for day 13 & 14 visits | 0 | 0 | 1 | 0 |
| Withdrew: Family emergency abroad | 0 | 0 | 0 | 1 |
| mmHg | Amlodipine+Celecoxib | Amlodipine+Placebo | Placebo+Celecoxib | Placebo+Placebo |
|---|---|---|---|---|
| Mean Change in Average Daytime (9:00 to 21:00) Ambulatory Systolic Blood Pressure (SBPday) - Primary Endpoint | -10.6 ± 9.2 | -8.83 ± 8.13 | -0.5 ± 8.8 | -2.11 ± 8.2 |
Including any untoward medical occurrence in a participant administered study drug, which do not necessarily have a causal relationship with the study drug \[i.e., any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug, whether or not related to the study drug\].
| Participants | Amlodipine+Celecoxib | Amlodipine+Placebo | Placebo+Celecoxib | Placebo+Placebo |
|---|---|---|---|---|
| Frequency of Adverse Events (Number of Participants Affected/Number of Participants at Risk) | 27 | 28 | 14 | 10 |
| mmHg | Amlodipine+Celecoxib | Amlodipine+Placebo | Placebo+Celecoxib | Placebo+Placebo |
|---|---|---|---|---|
| Mean Change in Average 24-hour Ambulatory Systolic Blood Pressure (SBP24h) | -10.3 ± 8.9 | -8.02 ± 7.6 | -0.5 ± 7.8 | -1.19 ± 5.87 |
| mmHg | Amlodipine+Celecoxib | Amlodipine+Placebo | Placebo+Celecoxib | Placebo+Placebo |
|---|---|---|---|---|
| Mean Change in Average Night-time (01:00 to 06:00) Ambulatory Systolic Blood Pressure (SBPnight) | -10.5 ± 10.6 | -6.35 ± 11.35 | -1.7 ± 12.3 | -1.42 ± 9.15 |
| mmHg | Amlodipine+Celecoxib | Amlodipine+Placebo | Placebo+Celecoxib | Placebo+Placebo |
|---|---|---|---|---|
| Mean Change in Average 24-hour Ambulatory Diastolic Blood Pressure (DBP24h) | -7.1 ± 5.6 | -4.8 ± 4.83 | -0.5 ± 4.6 | 0.22 ± 4.28 |
| mmHg | Amlodipine+Celecoxib | Amlodipine+Placebo | Placebo+Celecoxib | Placebo+Placebo |
|---|---|---|---|---|
| Mean Change in Average Daytime (9:00 to 21:00) Ambulatory Diastolic Blood Pressure (DBPday) | -7.5 ± 6.4 | -5.53 ± 5.06 | -1.5 ± 5.6 | -0.32 ± 5.39 |
| mmHg | Amlodipine+Celecoxib | Amlodipine+Placebo | Placebo+Celecoxib | Placebo+Placebo |
|---|---|---|---|---|
| Mean Change in Average Night-time (01:00 to 06:00) Ambulatory Diastolic Blood Pressure (DBPnight) | -7.0 ± 8.6 | -3.23 ± 7.79 | 0.3 ± 7.1 | 0.01 ± 6.23 |
| pg/mL | Amlodipine+Celecoxib | Amlodipine+Placebo |
|---|---|---|
| Mean Non-transformed Amlodipine Plasma Concentration | 15,800.83 ± 4,161.929 | 23,453 ± 5,746.337 |
| ng/mL | Amlodipine+Celecoxib | Placebo+Celecoxib |
|---|---|---|
| Mean Non-transformed Celecoxib Plasma Concentration | 139.708 ± 86.504 | 138.667 ± 118.811 |
| log(pg/mL) | Amlodipine+Celecoxib | Amlodipine+Placebo |
|---|---|---|
| Mean Log-transformed Amlodipine Plasma Concentration | 9.634 ± 0.268 | 10.025 ± 0.310 |
| log(ng/mL) | Amlodipine+Celecoxib | Placebo+Celecoxib |
|---|---|---|
| Mean Log-transformed Celecoxib Plasma Concentration | 4.785 ± 0.564 | 4.636 ± 0.781 |
| mmHg | Amlodipine+Celecoxib | Amlodipine+Placebo | Placebo+Celecoxib | Placebo+Placebo |
|---|---|---|---|---|
| Mean Change in Average Daytime (9:00 to 21:00) Ambulatory Systolic Blood Pressure (SBPday) - Secondary Endpoint | -10.6 ± 9.2 | -8.83 ± 8.13 | -0.5 ± 8.8 | -2.11 ± 8.2 |
Collected over 1 month. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Amlodipine+Celecoxib | 0/49 (0%) | 0/49 (0%) | 17/49 (34.7%) |
| Amlodipine+Placebo | 0/45 (0%) | 0/45 (0%) | 17/45 (37.8%) |
| Placebo+Celecoxib | 0/31 (0%) | 0/31 (0%) | 5/31 (16.1%) |
| Placebo+Placebo | 0/27 (0%) | 0/27 (0%) | 6/27 (22.2%) |
| Event | Amlodipine+Celecoxib | Amlodipine+Placebo | Placebo+Celecoxib | Placebo+Placebo |
|---|---|---|---|---|
| Oedema peripheralGeneral disorders | 4/49 | 7/45 | 0/31 | 0/27 |
| HeadacheNervous system disorders | 4/49 | 6/45 | 2/31 | 2/27 |
| NasopharyngitisInfections and infestations | 5/49 | 0/45 | 2/31 | 0/27 |
| Joint swellingMusculoskeletal and connective tissue disorders | 5/49 | 3/45 | 0/31 | 0/27 |
| DiarrhoeaGastrointestinal disorders | 2/49 | 4/45 | 0/31 | 0/27 |
| GoutMetabolism and nutrition disorders | 0/49 | 0/45 | 0/31 | 2/27 |
| Orthostatic hypotensionVascular disorders | 0/49 | 2/45 | 0/31 | 2/27 |
| Upper respiratory tract infectionInfections and infestations | 0/49 | 2/45 | 2/31 | 1/27 |
| Age, Continuous(years) | Amlodipine+Celecoxib | Amlodipine+Placebo | Placebo+Celecoxib | Placebo+Placebo | Total |
|---|---|---|---|---|---|
| Mean | 57.7 ± 8.0 | 57.3 ± 9.4 | 54.9 ± 8.2 | 52.5 ± 9.1 | 56.1 ± 8.8 |
| Sex: Female, Male(Participants) | Amlodipine+Celecoxib | Amlodipine+Placebo | Placebo+Celecoxib | Placebo+Placebo | Total |
|---|---|---|---|---|---|
| Female | 17 | 19 | 10 | 10 | 56 |
| Male | 32 | 26 | 21 | 17 | 96 |
| Race (NIH/OMB)(Participants) | Amlodipine+Celecoxib | Amlodipine+Placebo | Placebo+Celecoxib | Placebo+Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 3 | 0 | 1 | 1 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 1 | 0 | 3 |
| White | 46 | 43 | 29 | 26 | 144 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Amlodipine+Celecoxib | Amlodipine+Placebo | Placebo+Celecoxib | Placebo+Placebo | Total |
|---|---|---|---|---|---|
| United Kingdom | 49 | 45 | 31 | 27 | 152 |
| Average Daytime (9:00 to 21:00) Ambulatory Systolic Blood Pressure (SBPday)(mmHg) | Amlodipine+Celecoxib | Amlodipine+Placebo | Placebo+Celecoxib | Placebo+Placebo | Total |
|---|---|---|---|---|---|
| Mean | 148.7 ± 7.4 | 147.6 ± 8.7 | 150.8 ± 8.9 | 147.3 ± 8.6 | 148.5 ± 8.4 |
Ran from Jun 2014 to primary completion in Nov 2015, 16 months.
Results were first posted in Oct 2017, 1 year 10 months after primary completion.
Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 16 months is below that.
Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Amlodipine · Celecoxib